The FDA on May 27, 2022, approved the following for the first-line treatment of patients with advanced or metastatic Esophageal Squamous Cell Carcinoma (ESCC):
1) OPDIVO® (Nivolumab) in combination with Fluoropyrimidine and platinum-based chemotherapy
2) OPDIVO® in combination with YERVOY® (Ipilimumab) (Yervoy, Bristol-Myers Squibb Company)
OPDIVO® and YERVOY® are products of Bristol-Myers Squibb Company
